R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

Immunometabolism: Providing a new era of targeted medicine

In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh speaks with Neil Weir, CEO of Sitryx Therapeutics, a smaller biotech that specialises in immunometabolism – a rapidly

R&D

Modernising clinical trials: The PARTICIPATE framework

Each year, a staggering 67 million individuals lose their lives.1 Heart disease account for approximately 17.9 million of these deaths,2 and cancer takes away 10 milli

R&D

The evolving landscape of medicinal cannabis and its synergy...

The journey of medicinal cannabis has seen remarkable adoption worldwide.

R&D

While diabetes & obesity fund Novo Nordisk, its Foundation f...

The Novo Nordisk Foundation is not a charitable organisation owned by the pharma company Novo Nordisk. In fact, it’s the other way around, more or less.

R&D

Attracting investors takes more than good science

Scientists in the C-Suite: Attracting investors takes more t...

In the ever-evolving landscape of the biotechnology sector, the ability to attract investors effectively stands as the decisive factor that separates the success of your pioneering research

R&D